Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects.

April 10, 2024

Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell...

Stamford Expands its Scientific Advisory Team

April 1, 2024

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies, focused on cutaneous and visceral cancers, today announced that...

Stamford Pharmaceuticals Inc announces Dr Jacques Banchereau at Chief Scientific Officer.

October 1, 2023

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies focused on cutaneous and visceral cancers, today announced the...